Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.
Lymphoma, Non-Hodgkin's
DRUG: PNT2258
Overall Response Rate, Subjects who had a best response of complete response or partial response as assessed by the investigator, 39 months
Progression-free Survival, The time from Cycle 1 Day 1 until the date of lymphoma progression or death from any cause, or to the last date at which progression status was adequately assessed for censored observation, 39 months
PNT2258 will be administered at a dose of 120 mg/m2, as a 3-hour intravenous (IV) infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.